Cardiovascular risk in patients with inflammatory arthritis

Cardiovascular risk in patients with inflammatory arthritis

Rheumatoid and other inflammatory arthritis (ankylosing spondylitis and psoriatic arthritis) have a high risk of cardiovascular disease (CVD). It is caused by the accelerated development of atherosclerosis associated with a chronic systemic inflammatory process. Nevertheless, traditional CVD risk fa...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. A. Anichkov, N. A. Shostak, V. T. Timofeev
Format:	Article
Language:	Russian
Published:	ABV-press 2024-02-01
Series:	Klinicist
Subjects:	rheumatoid arthritis psoriatic arthritis ankylosing spondylitis cardiovascular diseases risk factors coronary heart disease statins disease-modifying antirheumatic drugs biologics
Online Access:	https://klinitsist.abvpress.ru/Klin/article/view/574
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases
by: A. E. Karateev, et al.
Published: (2022-12-01)

Severe comorbid infections in patients with inflammatory joint diseases: frequency, structure, risk factors
by: M. M. Baranova, et al.
Published: (2025-04-01)

The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties
by: Garmish O, et al.
Published: (2025-08-01)

Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice
by: E. Yu. Loginova, et al.
Published: (2021-10-01)

Advances in the Drugs Treatment of Psoriatic Arthritis
by: LU Chaofan, et al.
Published: (2024-12-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Pharmacoeconomic study of active psoriatic arthritis treatment
by: A. V. Rudakova, et al.
Published: (2025-02-01)

Targeted Therapy for Rheumatoid Arthritis in the New Era
by: WANG Jun, et al.
Published: (2025-01-01)

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA
by: T. V. Popkova, et al.
Published: (2016-07-01)

End-stage rheumatoid arthritis: specific features of patient management
by: Nadezhda Aleksandrovna Shostak, et al.
Published: (2013-06-01)

Enthesitis is a clue to the diagnosis of spondyloarthritis, focus on psoriatic arthritis
by: Ye. D. Yehudina, et al.
Published: (2021-02-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2021-06-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

Peculiarities of pharmacotherapy of patients with rheumatoid arthritis associated with interstitial lung disease
by: A. V. Gordeev, et al.
Published: (2024-02-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

Comorbid Infections in Spondyloarthritis: the Current State of the Problem
by: M. M. Baranova, et al.
Published: (2025-04-01)

The anti-inflammatory properties of simvastatin can benefit statin-naïve rheumatoid arthritis patients with associated risks for cardiovascular disease
by: A.O. Komolafe, et al.
Published: (2015-02-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
by: Suad Mohammed, et al.
Published: (2019-01-01)

Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system
by: E. A. Pyadushkina, et al.
Published: (2021-02-01)

MODERN VIEWS ON PATHOGENETIC THERAPY OF RHEUMATOID ARTHRITIS
by: D. G. Rekalov, et al.
Published: (2013-12-01)

Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry
by: T. V. Korotaeva, et al.
Published: (2021-02-01)

The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2016-10-01)

Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
by: Т. V. Korotaeva
Published: (2021-04-01)

Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study
by: Bessette L, et al.
Published: (2025-06-01)

Body composition and skeletal muscles status in patients with rheumatoid arthritis during treatment with biologic disease-modifying antirheumatic drugs
by: O. V. Dobrovolskaya, et al.
Published: (2025-02-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

Evaluation of the possibility of axial psoriatic arthritis patients meet classification criteria for axial spondyloarthritis and ankylosing spondylitis
by: E. E. Gubar, et al.
Published: (2023-08-01)

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01)

COVID-19 and post-covid syndrome in patients with rheumatoid arthritis
by: E. S. Aronova, et al.
Published: (2023-08-01)

Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy
by: M. M. Baranova, et al.
Published: (2024-06-01)

Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem
by: N. V. Chichasova, et al.
Published: (2024-12-01)

Real-World Safety and Efficacy of Targeted Therapies in Rheumatoid Arthritis: A 5-Year, 5130-Case Follow-Up from FIRST Registry
by: Koshiro Sonomoto, et al.
Published: (2025-04-01)

EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY
by: I. V. Shirinsky, et al.
Published: (2014-07-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
by: A. E. Karateev, et al.
Published: (2022-09-01)

Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
by: A. O. Bobkova, et al.
Published: (2024-08-01)

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
by: V. N. Amirdzhanova, et al.
Published: (2014-09-01)

Golimumab for Treating Chronic Inflammatory Joint Diseases in the Adult Population: Clinical Efficacy and Tolerability
by: Natal’ya N. Chichasova
Published: (2019-01-01)